Joshua Ofman Sells 9,692 Shares of GRAIL (NASDAQ:GRAL) Stock

Key Points

• Joshua Ofman, President of GRAIL, Inc., sold 9,692 shares of stock at an average price of $64.00, totaling $620,288, which decreased his holdings by 1.99% to 478,182 shares.
• GRAIL reported negative earnings of ($3.18) per share for the last quarter, missing estimates, with revenue of $35.54 million, below expectations of $37.57 million.
• Wall Street analysts have varying opinions on GRAIL, with some setting a price target of $75.00, while others maintain a "sell" rating, reflecting uncertainty about the company's performance.

GRAIL, Inc. (NASDAQ:GRAL - Get Free Report) President Joshua Ofman sold 9,692 shares of the stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $64.00, for a total value of $620,288.00. Following the completion of the sale, the president owned 478,182 shares in the company, valued at $30,603,648. This trade represents a 1.99% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

GRAIL Trading Up 1.3%

NASDAQ GRAL traded up $0.81 during trading hours on Friday, reaching $65.54. 2,168,076 shares of the stock traded hands, compared to its average volume of 949,119. The stock has a 50 day simple moving average of $38.69 and a two-hundred day simple moving average of $37.12. GRAIL, Inc. has a 1 year low of $12.33 and a 1 year high of $73.74.

GRAIL (NASDAQ:GRAL - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($3.18) earnings per share for the quarter, missing analysts' consensus estimates of ($3.14) by ($0.04). GRAIL had a negative net margin of 329.86% and a negative return on equity of 16.64%. The firm had revenue of $35.54 million for the quarter, compared to analysts' expectations of $37.57 million. Research analysts forecast that GRAIL, Inc. will post -15.15 EPS for the current fiscal year.

Institutional Trading of GRAIL

Several large investors have recently modified their holdings of GRAL. Nuveen Asset Management LLC bought a new stake in GRAIL during the 4th quarter valued at approximately $837,000. Two Sigma Advisers LP purchased a new position in shares of GRAIL during the fourth quarter valued at approximately $345,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of GRAIL during the fourth quarter valued at approximately $1,201,000. Public Employees Retirement System of Ohio purchased a new position in shares of GRAIL during the fourth quarter valued at approximately $334,000. Finally, California State Teachers Retirement System purchased a new position in shares of GRAIL during the fourth quarter valued at approximately $464,000.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Canaccord Genuity Group lifted their price objective on GRAIL from $43.00 to $75.00 and gave the stock a "buy" rating in a report on Friday. UBS Group set a $75.00 price objective on GRAIL in a report on Friday. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of GRAIL in a report on Saturday, September 27th. One equities research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $56.67.

GRAIL Company Profile

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.